Current and planned multicenter trials for patients with primary or metastatic melanoma

Authors

  • Vernon K. Sondak MD,

    Corresponding author
    1. The Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, Florida
    2. Department of Oncologic Sciences, University of South Florida College of Medicine, Tampa, Florida
    3. Department of Surgery, University of South Florida College of Medicine, Tampa, Florida
    • Department of Cutaneous Oncology, Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL 33612. Fax: 813-745-7211.===

    Search for more papers by this author
  • Dale Han MD,

    1. The Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, Florida
    Search for more papers by this author
  • Jeremiah Deneve DO,

    1. The Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, Florida
    Search for more papers by this author
  • Ragini Kudchadkar MD

    1. The Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, Florida
    2. Department of Oncologic Sciences, University of South Florida College of Medicine, Tampa, Florida
    Search for more papers by this author

  • Dr. Sondak has been a paid consultant and provided expert testimony for Merck/Schering-Plough. The other authors have no relevant disclosures.

Abstract

Multicenter clinical trials have established new standards of care in the surgical and medical management of malignant melanoma. They have led to the testing of new therapies and improved outcomes for patients with loco-regional and distant disease. Many pressing questions remain, however, and additional multicenter trials are currently underway to address them. The purpose of this review is to summarize relevant ongoing and planned multicenter trials that have and continue to define current melanoma management. J. Surg. Oncol. 2011; 104:430–437. © 2011 Wiley-Liss, Inc.

Ancillary